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Objective: To investigate the genetic contribution of cytokine gene polymorphisms (interleukin 1 (IL1) and
tumour necrosis factor a (TNFa)) on disease phenotype and on response to TNF-blocking agents in a
population of patients with juvenile idiopathic arthritis (JIA).
Methods: A cohort of 107 consecutive patients with JIA who were receiving treatment with anti-TNF agents
was enrolled in this study. Analysis of genetic polymorphisms for IL1B +3954, IL1RA +2018, TNFa 2238 and
TNFa 2308 was performed by enzyme-linked oligo sorbent assay, and compared with those obtained from
630 healthy Caucasians and 263 adult patients with rheumatoid arthritis. Relevant demographic, clinical and
laboratory data were collected from clinical charts and entered into a customised database, and x2 analysis
was performed to compare cytokine polymorphisms with disease type according to the International League
of Associations for Rheumatology criteria, presence of uveitis, rheumatoid factor and anti-nuclear antibody
positivity, erosive disease, frequency of adverse effects to anti-TNF and clinical response after 3 months.
Results: The T/T genotype of the IL1B +3954 polymorphism was absent in patients with JIA and present in 5%
of controls (p = 0.015). No significant correlation was found between the studied polymorphisms and clinical
or laboratory variables considered. Clinical response to TNF inhibitors at 3 months was not associated with
the genetic polymorphisms considered.
Conclusion: In our cohort, the absence of the rare IL1B +3954 gene polymorphism was associated with JIA,
but without specificity to particular disease phenotypes. The TNF and IL1 gene polymorphism studied did not
seem to be associated with response to anti-TNF treatment.
J
uvenile idiopathic arthritis (JIA) is characterised by chronic
arthritis of unknown aetiology with onset before 16 years of
age. Although a large percentage of patients can achieve
durable remissions, a substantial proportion will have progres-
sive joint destruction. JIA pathogenesis is complex and includes
genetic and environmental factors. Numerous major histocom-
patibility complex and non-major histocompatibility complex
associations have been described; however, different ethnic
populations, patient groupings, and systems of nomenclature
and classification all impose limitations to direct comparisons
of existing studies.1
Single nucleotide polymorphisms (SNPs) are single base
changes that can occur at any site in the DNA, and some of
these SNPs may influence variations in in vitro transcription or
protein synthesis, thereby differentially affecting inflammatory
processes and disease outcome. Cytokines such as IL1 and
TNFa are central mediators of joint inflammation in patients
with JIA, and different polymorphisms of these and other
cytokines have already been studied in patients with JIA.2–4
The availability of biological agents such as TNF inhibitors for
children has substantially improved the prognosis and quality
of life of paediatric patients with JIA, even after failure with
conventional second-line treatments, but the response to
treatment is not constant. The aim of the present study was
to investigate possible genetic contributions of selected cytokine
polymorphisms (IL1 and TNFa) on clinical response to TNF-
blocking agents in a population of patients with JIA. Moreover,
possible associations with particular JIA phenotypes were
investigated.
MATERIALS AND METHODS
Patients
A total of 107 patients with JIA who were receiving treat-
ment with anti-TNF agents in three tertiary care paediatric
rheumatology centres (Edouard Herriot, Lyon, France; Gaetano
Pini Hospital, Milan, Italy; and Department of Pediatrics,
University of Padova, Padova, Italy) during 2005 were enrolled.
All were classified according to the revised International League
of Associations for Rheumatology (ILAR) criteria for JIA.5
Parameters recorded included age, sex, disease category,
disease duration, presence of extra-articular manifestations
(namely, chronic uveitis) and treatment received. Biological
data included erythrocyte sedimentation rate, rheumatoid
factor, antinuclear antibodies (indirect immunofluorescence
on Hep2 cells, positivity .1:80), and IL1 and TNFa polymorph-
isms. Joint damage was evaluated by plain x rays, and
radiographic erosions were classified in a dichotomous manner
as either present or absent. Type and duration of anti-TNF
treatment, as well as possible side effects, was also recorded.
Infliximab therapy was given at the dosage of 3 mg/kg of
body weight according to a standardised protocol,6 etanercept
was given at the dosage of 0.4 mg/kg subcutaneously twice a
week and adalimumab was given at the dosage of 24 mg/m2
subcutaneously on alternate weeks. Clinical response to anti-
TNF was assessed after 3 months of therapy according to the
ACR Pedi 30 (American College of Rheumatology Pediatric
30%).7
A cohort of 263 adult patients with rheumatoid arthritis (RA)
followed up in Lyon was also studied, and the results were
compared with those obtained from patients with JIA. The
same genotyping was performed in 630 adult blood donors of
French origin, who acted as a control group.
Abbreviations: IL, interleukin; ILAR, International League of Associations
for Rheumatology; JIA, juvenile idiopathic arthritis; RA, rheumatoid
arthritis; SNP, single nucleotide polymorphism; TNFa, tumour necrosis
factor a
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Informed consent was obtained from parent or guardian, or
by the patients if they are aged .18 years. The protocol was
approved by the committee for protection of persons participat-
ing in biomedical research and by the ethical committees of the
participating hospitals.
Polymorphism and gene typing
Uncoagulated blood was taken from patients during routine
venipuncture, and stored frozen at 220 C˚ until DNA extraction.
DNA was extracted using the QIAamp DNA Blood Mini Kit
(Qiagen GmbH, Hilden, Germany), as recommended by the
manufacturer. A multiplex PCR amplification was performed
using three sets of primers to amplify a 245 bp sequence of the
IL1b gene, a 230 bp sequence of the IL1Ra gene and a 374 bp
sequence of the TNFa gene. PCR primers were as follows. IL1b
gene: 59 TTCAGTTCATATGGACCAGA 39; 59 GTTGTCATCAGA
CTTTGACC 39. IL1Ra gene: 59 GGGCACATGGTGGCTGTGCA 39;
59 ACCTAGGGTTTGTGCAGGCA 39. TNFa gene: 59 TCAACGG
ACTCA GCTTTCTGAA 39; 59 CGGAAAACTTCCTTGGTGGAG 39.
PCRs were performed in 100 ml reaction volume containing
100 ng of genomic DNA, 0.24 mM of deoxyribonucleotide
triphosphates (dNTPs), IL1b and IL1Ra primers at 0.36 mM
each, TNFa primers at 0.54 mM each and 2.5 units of Taq DNA
polymerase (Perkin Elmer, Waltham, Massachusetts, USA) in a
Bio-Rad thermal cycler (Bio-Rad Laboratories, Hercules,
California, USA). PCR cycles were as follows: (95 C˚, 2 min)
61; (94 C˚, 30 s; 55 C˚, 30 s; 68 C˚, 1 min) 640; and (68 C˚,
10 min) 61. The amplicon products of multiplex PCR were
genotyped by enzyme-linked oligo sorbent assay as previously
described.8
Statistical analysis
Relevant demographic, clinical and laboratory data were
collected from clinical charts and entered into a customised
Excel database. We performed x2 analysis to compare cytokine
polymorphisms with disease type (ILAR criteria), presence of
uveitis, rheumatoid factor and anti-nuclear antibody positivity,
radiographic erosive changes, frequency of adverse effects to
anti-TNF and clinical response after 3 months (ACR Pedi 30).
p Values ,0.05 were considered significant. Both genotypic
frequency (the frequency of a genotype in that population) and
allelic frequency (the frequency with which a particular allele
appears among the possible alleles in that population) were
considered in the statistical comparisons.
RESULTS
Characteristics of the patient population
A total of 107 patients with JIA (83 females, 24 males) were
included in the study, almost all (n = 103) were of Caucasian
origin. Mean (SD) age at disease onset was 6.5 (4.9) years
(range, 1 month–15 years), while mean age at onset of anti-
TNF treatment was 16.3 (8.1) years (range, 3–43 years). The
Gaetano Pini Hospital is a referral centre that includes an adult
rheumatology and a paediatric rheumatology unit, therefore
some patients with JIA who were diagnosed in childhood but
received anti-TNF treatment during adulthood in the same
centre were also included in this study. According to the ILAR
classification criteria, diagnoses were: systemic arthritis
(n = 29); persistent oligoarthritis (n = 4); extended oligoarthri-
tis (n = 27); rheumatoid factor-negative polyarthritis (n = 24);
rheumatoid factor-positive polyarthritis (n = 5); psoriatic
arthritis (n = 6); and enthesitis-related arthritis (n = 12). All
patients had active disease despite being treated with disease-
modifying antirheumatic drugs (notably, by definition, they all
had to have failed methotrexate treatment) before initiation of
anti-TNF therapy. In 16 cases, the disease course had been
complicated by the presence of chronic uveitis. Across patients,
71 had received etanercept, 34 infliximab and 2 adalimumab.
Table 1 summarises the general demographic and clinical
features of the study patients, in total, and subdivided by ILAR
classification.
Response to anti-TNF treatment after 3 months was positive
in 84/106 (79%) evaluable patients. It was not possible to
evaluate the response according to standardised criteria for only
one patient (lost to follow-up). There was no statistically
significant difference in response rates to the different anti-TNF
used (data not shown), nor any significant difference in
response among the different disease diagnoses.
IL1 and TNF gene polymorphisms and disease
phenotype
The results of cytokine polymorphisms on our patients were as
follows: for IL1b +3954: C/C 62 (58%), C/T 45 (42%), T/T 0 (0%);
for IL1RA +2018: C/C 8 (7%), C/T 50 (47%), T/T 49 (46%); for
TNFa –238: G/G 95 (90%), G/A 10 (9%), A/A 1 (1%); and for
TNFa –308: G/G 86 (81%), G/A 19 (18%), A/A 1 (1%).
When the SNPs considered were compared among patients
with JIA and healthy controls, we found that the T/T genotype
of the IL1B +3954 polymorphism was absent in our study
population and present in 5% of controls; this difference was
significant (p = 0.015; fig 1). The other SNPs considered did not
differ in patients and controls.
In addition, we compared these results with data obtained
from adult patients with RA followed up in Lyon, and found
that the prevalence of the A allele of the –238 TNF polymorph-
ism was 6% in those with JIA and 3% in those with RA
(p = 0.046; fig 1). All other allelic frequencies, and all genotypic
frequencies for the different polymorphisms were not statisti-
cally different between JIA and RA (data not shown).
With regard to our patients, no link was observed between
the TNF and IL1 SNPs and the selected clinical variables (data
not shown).
IL1 and TNF gene polymorphisms and response to TNF
inhibitors
When we compared the SNPs with clinical response after
3 months, we were not able to find significant differences both
for allelic and genotypic frequencies between responders and
non-responders (fig 2).
DISCUSSION
Genetic contribution in the susceptibility for JIA is well
established, and cytokine gene polymorphisms have been
studied by several groups. We focused on polymorphisms in
the IL1B gene (at +3954), in the IL1-RN gene (at +2018) and in
the TNFa promoter (at –238 and –308), as they had been
already studied in patients with RA, and previously described as
severity markers.9 We were able to find a statistical difference
between our patient group and healthy blood donors with
regard to the IL1B +3954 genotype, in that the T/T genotype was
not present in any of our cases.
Most of the studies on cytokine gene polymorphisms in JIA
were limited to the study of one or two cytokines, with only few
comprehensive studies being performed.2–4 In our study, we did
not find any association between the SNPs that we analysed
and disease phenotype or severity; however, our study popula-
tion was, by definition, already selected, in that all patients
were receiving anti-TNF treatment, and therefore already had a
severe and progressive disease. A direct comparison of our
result with a previous series is therefore not possible. Moreover,
it is widely acknowledged that JIA is not a single disease but a
term that encompasses several categories, now often repre-
sented within the ILAR classification. This is of interest as it is
known that pathogenesis and response to treatment might
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Table 1 General demographic and clinical features of the study patients, in the whole group
and subdivided by International League of Associations for Rheumatology classification
JIA SoJIA PO ExO RFneg RFpos PsA ERA
N˚ patients 107 29 4 27 24 5 6 12
Male 24 10 0 2 3 1 1 7
Female 83 19 4 25 21 4 5 5
Disease duration at onset anti-
TNF therapy (Mean (SD), years
9.8 (8.7) 9.6 (8.1) 5 (2.8) 11.3 (8) 8.7 (7.2) 6.1 (4) 20 (9.7) 7.2 (5)
Anti-TNF type
Infliximab 34 8 1 8 6 3 5 3
Etanercept 71 19 3 19 18 2 1 9
Adalimumab 2 2 0 0 0 0 0 0
Uveitis
Yes 16 1 3 7 2 0 2 1
No 91 28 1 20 22 5 4 11
Erosions
Yes 49 17 1 12 9 2 5 3
No 30 5 2 13 8 1 1 0
Complications of anti-TNF
treatment
Yes 28 11 1 6 3 2 4 1
No 77 18 2 20 21 3 2 11
Response to anti-TNF at 3 months
Yes 84 19 3 25 19 3 6 9
No 22 10 1 2 4 2 0 3
Not applicable 1 0 0 0 1 0 0 0
ERA, enthesitis-related arthritis; ExO, extended oligoarthritis; JIA, juvenile idiopathic arthritis (total); PO, persistent
oligoarthritis; PsA, psoriatic arthritis; RFneg, polyarthritis RF-negative; RFpos, polyarthritis RF-positive; SoJIA, systemic
arthritis.
There was no patient with undifferentiated arthritis. Erosions have been evaluated in 79 patients, complications in 105
and clinical response in 106.
Figure 1 Distribution of frequencies of
selected interleukin (IL) 1 and tumour
necrosis factor a (TNFa) gene
polymorphisms in patients with juvenile
idiopathic arthritis (JIA), rheumatoid arthritis
(RA) and healthy controls. (A) Genotypic
frequencies: difference for IL1b +3954
polymorphism between patients with JIA and
controls (p = 0.015). (B) Allelic frequencies:
difference for TNFa –238 polymorphism
between patients with JIA and those with RA
(p = 0.046).
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differ among these groups; in particular, it has been recently
shown that systemic-onset disease might be mediated by IL1
and might respond to IL1 blockage.10 However, in our series,
even if there was a trend towards a difference in clinical
response to anti-TNF between patients with systemic-onset JIA
and those with other JIAs, this did not reach significance
(p = 0.06), maybe because of an insufficient sample size.
The use of therapies targeting TNF has remarkably improved
the prognosis of JIA; however, clinical responses to TNF
inhibitors are variable among patients.11 There is no evidence
that simple determination of plasma TNFa levels by ELISA
allows such prediction for treatment with TNFa inhibitors.12
However, recent results from our laboratory have indicated
that, using a functional cell-based assay, it is possible to link
the response to TNF inhibitor infliximab to the functional
circulating level of TNF activity in plasma, with patients with
high circulating levels of TNF activity being more susceptible to
respond to TNF inhibition.12
Therefore, the contribution of cytokine polymorphisms to the
response to anti-TNF is of interest, but to date no disease-
related features, patient characteristics, genetic associations or
other factors that reliably correlate with treatment outcome
have been identified.13 We were not able to find a link between
any of the selected cytokine SNPs (in particular, a polymorph-
ism at the TNF locus) and clinical response to anti-TNF. All of
our patients, despite different onset types, had a severe and
polyarticular disease, and were therefore grouped together for
this particular analysis. In a previous study from our hospital
on patients with RA,8 no association between the same SNPs
and response to anti-TNF was found. In a study from another
French group14 performed on 59 patients with RA, those
carrying the rare allele A were two times more likely to have
no response to infliximab than those with the common G/G
genotype of the –308 TNFa polymorphism. In another cohort of
110 patients with RA treated with infliximab, a relationship
was detected between ACR criteria of improvement and
increased circulating TNFa levels, but not between TNFa
promoter SNPs and clinical response.15 Also, Criswell et al16
showed that an extended haplotype, which included HLA-
DRB1 alleles and SNPs in the lymphotoxin TNFa region
(including those at position –238 and –308), was associated
with the response to treatment with methotrexate or etaner-
cept, even if the precise genetic markers on this extended
haplotype and their mechanism of action related to RA
treatment response remained to be defined.
Perhaps not single SNPs but rather a combination of them
might be more useful in predicting a clinical response, such as
those seen in the study by Padyukov et al17 who found that TNF
and IL10 SNPs did predict clinical response to etanercept only
when the combined genotype was considered. Finally, there are
several polymorphic sites within the TNF locus, and preliminary
results suggest that other TNF SNPs may predict clinical
response to etanercept in RA.18
TNFa gene polymorphisms have already been studied in
JIA,19 but to our knowledge there is only one other published
study focusing on cytokine SNPs and response to anti-TNF in
Figure 2 (A) Comparison of genotypic
frequencies of selected IL1 and TNFa gene
polymorphisms with clinical response to anti-
TNF agents. (B) Comparison of allelic
frequencies of selected interleukin (IL) 1 and
tumour necrosis factor a (TNFa) gene
polymorphisms with clinical response to anti-
TNF agents.
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JIA.20 We acknowledge some limits of our study, such as
heterogeneity of study population in terms of disease onset
type. However, we have selected only patients who had a
polyarticular course and who had symptoms severe enough to
receive anti-TNF treatment. Moreover, all our healthy controls
were of French and not Italian origin; however, the statistical
difference between patients and controls was not influenced by
the ethnic origin of the patients (data not shown).
In summary, our study showed that the absence of the rare
IL1B +3954 gene polymorphism was associated with JIA, but
without specificity to particular disease phenotypes. The
studied TNF and IL1 gene polymorphisms did not seem to be
associated with the response to anti-TNF treatment. We are
currently studying other genetic and biological factors that
might predict the clinical response to anti-TNF, in order to be
able to tailor specific treatments based on individual patient
profile.
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